Re. There is no reason or purpose atm for additional funds
The single biggest bottleneck IMO to achieve share price appreciation is speed of execution: RAC needs to significantly derisk by moving as many existing pillars toward end of clinical trials - and also materialise revenue opportunities by working on more pillars.
I cannot help but think that more well-spent capital could help RAC to deliver value quicker, in one way or another. Right now with a market cap of ~230M, RAC's annual budget of ~4-5M seems very shy and could get a little cash boost without diluting too much (especially if done with existing shareholders using a SPP). Granted, wombat previously hinted that the Board does not wish to diluate capital more than necesary.
Of course, I am biased. As an investor, I tend to look at 12-24 months return window max. I really wish to see significant SP progress on the back of FTO and Breast Cancer pillars by then.
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-2997
-
- There are more pages in this discussion • 19,463 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.79 |
Change
0.010(0.56%) |
Mkt cap ! $304.2M |
Open | High | Low | Value | Volume |
$1.78 | $1.80 | $1.78 | $106.4K | 59.41K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 10000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 1.780 |
1 | 1690 | 1.775 |
1 | 11200 | 1.770 |
1 | 300 | 1.765 |
1 | 569 | 1.755 |
Price($) | Vol. | No. |
---|---|---|
1.830 | 10000 | 2 |
1.840 | 1400 | 2 |
1.880 | 2351 | 1 |
1.895 | 7800 | 1 |
1.900 | 159 | 1 |
Last trade - 15.57pm 30/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |